~~<i id='26B14AA295'><strike id='26B14AA295'><tt id='26B14AA295'><pre id='26B14AA295'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：leisure time 2025-10-02 08:13:25 Page View：557

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why some fertility treatments produce more boy babies
Next article： In age of alternative facts, a scholarly course on calling out crap

comprehensive

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Medical students need to learn the potent medicine of empathy

JoeRaedle/GettyImagesAfewyearsagoatalargeteachinghospitalinTexas,amedicalresidentaskedanursehowtoord

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Some medical students still think black patients feel less pain

APStockBlackpatientsaresystematicallyundertreatedforpain,decadesofresearchhaveshown.Andastudypublish